surmount-1 tirzepatide trial obesity without diabetes as Compared with Semaglutide for the Treatment of SURMOUNT-4 results just published in
Description
Lost about 6 lbs my first 3 weeks
Most gastrointestinal events were mild to moderate in severity and decreased over time as patients developed tolerance
Current NHS guidance for healthcare professionals recommends: Informing patients about the symptoms of pancreatitis before starting treatment Avoiding tirzepatide in patients with a history of pancreatitis, if possible Monitoring patients closely when initiating or increasing doses Discontinuing tirzepatide if pancreatitis is diagnosed These guidelines reflect the balanced approach of recognising the small risk while enabling appropriate patients to benefit from treatment
But heres the silver lining: all that weight she lost and the improved insulin sensitivity made it EASIER to control her blood sugar with the pregnancy-safe insulin
Key Points: Tirzepatide is a once-weekly medication that is administered as a subcutaneous injection (under the skin) using a pre-filled pen
For many living with severe asthma, daily life can feel like a balancing act between managing symptoms and coping with the side effects of treatment
